Close Menu

NEW YORK (GenomeWeb) – Cynvenio Biosystems announced today that it has launched a pilot surveillance study with South Korea's ATGen Global to evaluate a new method for the early detection of cancer recurrence in triple-negative breast cancer patients. Cynvenio's ClearID test will be combined with ATGen's NK Vue blood test to detect cancer recurrence in women who have previously been treated for triple-negative breast cancer and show no radiographic signs of metastases.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.